Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines.

about

Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines.

Item

http://www.wikidata.org/entity/Q47098234

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Increased EGFR Phosphorylation ...... istant Lung Cancer Cell Lines.

@en

Increased EGFR Phosphorylation ...... istant Lung Cancer Cell Lines.

@nl

type

Item

label

Increased EGFR Phosphorylation ...... istant Lung Cancer Cell Lines.

@en

Increased EGFR Phosphorylation ...... istant Lung Cancer Cell Lines.

@nl

prefLabel

Increased EGFR Phosphorylation ...... istant Lung Cancer Cell Lines.

@en

Increased EGFR Phosphorylation ...... istant Lung Cancer Cell Lines.

@nl

P1476

Increased EGFR Phosphorylation ...... istant Lung Cancer Cell Lines.

@en

P2093

Christopher J Rivard

http://www.w3.org/2001/XMLSchema#string

Fred R Hirsch

http://www.w3.org/2001/XMLSchema#string

Hui Yu

http://www.w3.org/2001/XMLSchema#string

Kim Ellison

http://www.w3.org/2001/XMLSchema#string

Koh Furugaki

http://www.w3.org/2001/XMLSchema#string

Leslie Rozeboom

http://www.w3.org/2001/XMLSchema#string

Mary Ann C Melnick

http://www.w3.org/2001/XMLSchema#string

Tetsuya Mitsudomi

http://www.w3.org/2001/XMLSchema#string

P2860

Subsets of epidermal growth factor receptors during activation and endocytosis

Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer

Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.

Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity.

Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.

PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.

Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.

EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB.

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.

P304

7694202

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2017/7694202

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

2017

http://www.w3.org/2001/XMLSchema#string

P50

Kenichi Suda

Katerina Politi

P577

2017-10-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29119113

http://www.w3.org/2001/XMLSchema#string

P932

5651099

http://www.w3.org/2001/XMLSchema#string